Actinogen Medical Ltd ACW:ASX

*Data is delayed | AUD
Last | 12:19 PM AET
0.097quote price arrow down-0.008 (-7.62%)
Volume
10,683,710
52 week range
0.02 - 0.20

...

Loading . . .
  • Open0.105
  • Day High0.105
  • Day Low0.092
  • Prev Close0.105
  • 52 Week High0.20
  • 52 Week High Date06/08/21
  • 52 Week Low0.02
  • 52 Week Low Date02/03/21

Key Stats

  • Market Cap112.26M
  • Shares Out1,450.79M
  • 10 Day Average Volume3.38M
  • Dividend-
  • Dividend Yield-
  • Beta1.05
  • YTD % Change361.9

KEY STATS

  • Open0.105
  • Day High0.105
  • Day Low0.092
  • Prev Close0.105
  • 52 Week High0.20
  • 52 Week High Date06/08/21
  • 52 Week Low0.02
  • 52 Week Low Date02/03/21
  • Market Cap112.26M
  • Shares Out1,450.79M
  • 10 Day Average Volume3.38M
  • Dividend-
  • Dividend Yield-
  • Beta1.05
  • YTD % Change361.9

RATIOS/PROFITABILITY

  • EPS (TTM)-0.00
  • P/E (TTM)-34.64
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Actinogen Medical Ltd

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Actinogen Medical Limited, formerly Actinogen Limited, is a clinical-stage biotechnology company. The Company focuses on the treatment of Alzheimer's disease and age-related neurodegenerative diseases. The Company is engaged in treating cognitive impairment in chronic neurodegenerative diseases through the inhibition of cortisol production. The Company's Xanamem is a drug under development for the treatment of Alzheimer's disease, which is designed to block the production of...
Geoffrey Brooke M.D.
Non-Executive Chairman
Steven Gourlay
Chief Executive Officer
Jeff Carter
Chief Financial Officer
Address
Select House
SE 901 L 9, 109 Pitt Street
Sydney, NSW
2000
Australia